Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study

BMC Cancer

Table 1 Baseline characteristics of study cohort

Characteristic*	All patients (n = 355)
	N	%
Age in years
< 55	92	26
55-64	106	30
65-74	94	27
≥ 75	63	18
ACE-27 Comorbidity Index (score)
None (0)	120	34
Mild (1)	140	39
Moderate (2)	51	14
Severe (3)	44	12
Race
Non-white	134	38
White	221	62
Gender
Female	120	34
Male	235	66
Insurance
Missing	19	5
Public	45	13
Medicare + Supplemental	96	27
Veterans Administration	67	19
Private	128	36
Geographic region
West/Midwest	178	50
South	91	26
Atlantic	86	24
Health system
Fee-for-Service	212	60
Integrated health system	143	40
Annual household income
Missing	66	19
< $20,000/year	100	28
≥ $20,000/year	189	53
Diagnosis of metastatic disease
Recurrence	58	16
Stage IV at diagnosis	297	84
Primary tumor site
Missing	5	1
Colon	258	73
Rectum	76	21
Colorectal	16	5
Receipt of surgery within 4 weeks of chemotherapy
No qualifying surgery within 4 weeks	321	90
Qualifying surgery within 4 weeks	34	10
Presence of any of following 5 cardiovascular risks
No risk factor grade > 0	181	51
Presence of ≥ 1 risk factor grade > 0	174	49
Hypertension
Grade 0	203	57
Grade > 0	152	43
Angina/coronary artery disease
Grade 0	307	87
Grade > 0	48	14
Venous disease including venous thrombosis
Grade 0	346	98
Grade > 0	9	3
Peripheral artery disease
Grade 0	345	97
Grade > 0	10	3
Congestive heart failure
Grade 0	342	96
Grade > 0	13	4

*Only three patients had missing insurance data after imputation. The composition of health systems in the health system categorization of fee-for-services vs. integrated has been previously described [8]. Comorbidity was calculated using the Adult Comorbidity Evaluation-27 (ACE-27) index [11]. The cardiovascular comorbidities were collected as a part of the ACE-27. Some percentages may not sum to 100 due to rounding.

ISSN: 1471-2407